Article Text

Download PDFPDF

P3.449* The promise of estriol cream for prevention of vaginal infection in premenopausal women
  1. I. G. Dzuba1,
  2. H. Jones2,
  3. S. A. Ballagh3,
  4. W. H. Clark4,
  5. S. Hillier5,
  6. T. Irwin6,
  7. P. Marx7,
  8. S. Smith8,
  9. R. S. Veazey9,
  10. B. Winikoff1
  1. 1Gynuity Health Projects, New York, NY, United States
  2. 2CUNY School of Public Health at Hunter College, New York, NY, United States
  3. 3Los Angeles County Harbor-UCLA Medical Center, Torrance, CA, United States
  4. 4New York Presbyterian Hospital, New York, NY, United States
  5. 5Magee-Womens Research Institute, Pittsburgh, PA, United States
  6. 6University of Illinois at Chicago, Chicago, IL, United States
  7. 7Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, United States
  8. 8Smith Center for Infectious Diseases and Urban Health, East Orange, NJ, United States
  9. 9Tulane National Primate Research Center, Covington, LA, United States.


Background Vaginal epithelium thins during the luteal phase of the menstrual cycle, increasing susceptibility to vaginal infection. Exogenous oestrogen thickens vaginal epithelium in ovariectomized monkeys and protects against SIV transmission. While topical oestrogen has beneficial effects on vaginal health in postmenopausal women, its effects in pre-menopausal women are uncertain. This randomised controlled trial evaluated thickening and maturation effects of estriol cream on vaginal epithelium and changes in microflora in premenopausal women.

Methods Eligible women made visits in follicular and luteal phases before and after randomization to estriol cream (1mg estriol/1ml cream) or matching placebo. Women applied 4mg cream 3 times weekly for approximately 6 weeks before follow-up visits. Vaginal biopsies were collected for analysis of epithelial thickness and cell layers. Swabs were collected for Gram stain (scored by Nugent’s criteria) and for aerobic and anaerobic bacterial culture. Pearson’s t-test was used to compare means, Fishers exact test to compare proportions, and generalised estimating equations to compare person-weeks of cream use to pre-cream person-weeks.

Results 102 eligible women were enrolled; 83% (85) completed the study. With estriol, average epithelial thickness increased (27.5 μm, 95% CI 9.7–45.4), as did transitional cell layers (1.3, 95% CI 0.6–2.0), compared to baseline, with no changes among placebo users. E. coli colonisation increased among placebo users compared to baseline (OR 4.9, 95% CI 2.7–8.9), but not among estriol users (OR 0.98, 95% CI 0.4–2.2). The presence of white blood cells decreased only with estriol cream relative to baseline (OR 0.25 95% CI 0.11–0.55). No serious adverse events were reported and adverse events did not differ by study group.

Conclusion Vaginally-applied estriol cream safely increases epithelial thickness in luteal phase, mitigates the E. coli colonisation associated with use of other vaginal products, and has favourable immunological effects. Estriol holds promise to enhance vaginal infection prevention.

  • premenopausal women
  • STI Prevention
  • topical estrogen

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.